While the inventors of CRISPR tussle over ownership of the gene editing technology, Cellectis S.A. thinks it has a trump card that the winner of the CRISPR dispute will need to license in order to...

Cellectis granted genOway an exclusive sublicense to Cellectis' homologous recombination technology for research applications in genetically modified rodents. Under the deal, genOway will be the exclusive service provider and distributor of the technology to academic...

genOway received exclusive, worldwide rights to StemCells' Internal Ribosome Entry Site (IRES) technology to develop and commercialize genetically engineered mice. The technology genetically modifies any mammalian cells to enable dual expression of a protein of...

bluebird granted genOway exclusive, worldwide rights to its RMCE technology for use in genetically modified rodents. RMCE technology combines a recombinase system with genetic modification to enable the reliable and quick introduction of a DNA...

BioLineRx acquired exclusive rights to cancer candidate BL-7030 from Algen. The double-stranded RNA vector targeting EGFR is in preclinical testing. Algen has rights from the Hebrew University of Jerusalem (Jerusalem, Israel). Further terms were not...

In January, Genfit said it would receive €4.9 million ($6.6 million) in funding over four years from France's OSEO agency as part of the micro-Path translational research program to discover new biomarkers of cardiovascular disease....

genOway received contracts totalling €400,000 ($484,300) from three undisclosed Japanese biopharmaceutical companies to develop genetically modified animal models for testing pharmaceutical compounds. Further details were not disclosed. genOway S.A. (Euronext:ALGEN), Lyon, France Business: Functional genomics...

genOway and the university partnered to use autologous olfactory adult stem cells to establish germline transmission in rats. Both partners are responsible for their respective R&D costs. genOway will receive an exclusive, worldwide license to...

The companies settled a dispute concerning Cellectis' 2009 termination of a 2001 deal that granted genOway a non-exclusive license to Cellectis' homologous recombination technology for cellular and animal model development. The deal will remain terminated,...

Paris' Tribunal de Grande Instance dismissed genOway's lawsuit that challenged Cellectis' termination of a 2001 deal between the companies. In January, Cellectis ended its non-exclusive license deal with genOway, covering the use of homologous recombination...